Consequently, the time required for complete regression of secondary tumors was significantly lower in NE/CAMP +aPD‐1 group than in other groups (Figure S4e), indicating that the combination treatment induced a stronger long‐term anti‐tumor immune response against subcutaneously inoculated GL261. Here, CAMP is linked to neoplasm.